Active, Not Recruiting
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
NCT05480384
- Conditions
- Adenocarcinoma Of Esophagus, Digestive System Diseases, Digestive System Neoplasms, +11 more
- Locations
-
- Weill Cornell Medicine/New York-Presbyterian New York, United States
- Lifespan Cancer Institute Providence, Rhode Island, United States